Product Information
CEVIMELINE HCL 30 MG CAPSULE is a generic product labeled by Bionpharma Inc., priced at $0.7080 per EA under NDC 69452031620. Its NADAC has been published 119 times since May 15, 2024.
FDA first approved this application on Nov 8, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Bionpharma Inc.NDC
69452031620
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
CEVIMELINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA218290FDA Approved
11/8/2023
TE Code
AB
On Market Since
1/17/2024
Pharmacological Classes
Price Statistics
The NADAC for CEVIMELINE HCL 30 MG CAPSULE has been published 119 times since May 15, 2024, and over the history we have for it it has declined 13.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7080 per EA |
|---|---|
| All-time high | $1.0154 (Sep 11, 2024) |
| All-time low | $0.6268 (Nov 20, 2024) |
| 52-week high | $0.7172 |
| 52-week low | $0.6572 |
| Median price | $0.7079 |
| Average price | $0.7481 |
| Largest weekly change | -27.7% (Nov 20, 2024) |
| Weeks tracked | 119 |
| Tracking since | May 15, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of CEVIMELINE HCL 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CEVIMELINE HCL 30 MG CAPSULE, manufactured by Bionpharma Inc., is $0.7080 per EA (NDC 69452031620), effective Aug 19, 2026.
How has the price of CEVIMELINE HCL 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CEVIMELINE HCL 30 MG CAPSULE has declined 13.5%. It has been tracked across 119 weekly CMS publications since May 15, 2024.
What are the highest and lowest recorded NADAC prices for CEVIMELINE HCL 30 MG CAPSULE?
Since May 15, 2024, the NADAC for CEVIMELINE HCL 30 MG CAPSULE has ranged from a low of $0.6268 (Nov 20, 2024) to a high of $1.0154 (Sep 11, 2024), with a median of $0.7079 per EA.
Are there cheaper alternatives to CEVIMELINE HCL 30 MG CAPSULE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as CEVIMELINE HCL 30 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures CEVIMELINE HCL 30 MG CAPSULE?
CEVIMELINE HCL 30 MG CAPSULE (NDC 69452031620) is labeled by Bionpharma Inc., and CMS classifies it as a generic product.